Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 301–400 of 1,004
Protein–Energy Malnutrition: A Risk Factor for Various Ailments
Batool, R., Butt, M. S., Sultan, M. T., Saeed, F., & Naz, R. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.651543 · Cited by 122
Tai, D. J., Lim, T. W., James, M. T., Manns, B., Tonelli, M. A., & Hemmelgarn, B. R. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07831109 · Cited by 107
Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality
Lee, P., Sampath, K., Karumanchi, S. A., Tamez, H. E., Bhan, I., Isakova, T., Gutiérrez, O. M., Wolf, M. S., Chang, Y., Stossel, T. P., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008091008 · Cited by 110
Nanayakkara, P. W. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1262 · Cited by 107
Early detection of CKD: the benefits, limitations and effects on prognosis
Levin, A., & Stevens, P. E. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.86 · Cited by 121
Management of cardiovascular disease in patients with kidney disease
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15 · Cited by 115
Güder, G., Frantz, S., Bauersachs, J. K., Allolio, B., Wanner, C., Koller, M., Ertl, G., Angermann, C. E., & Störk, S. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.825059 · Cited by 120
Self-citationTuttle, K. R., & Short, R. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01250209 · Cited by 107
Vecchio, L. D., Locatelli, F., & Carini, M. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00819.x · Cited by 118
The Case against Calcium-Based Phosphate Binders
Moe, S. M., & Chertow, G. M. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00560206 · Cited by 106
Yamada, S., Ishii, H., Takahashi, H., Aoyama, T., Morita, Y., Kasuga, H., Kimura, K. B., Ito, I., Takahashi, R., Toriyama, T., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00050110 · Cited by 117
Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease
Ravid, J. D., Kamel, M. H., & Chitalia, V. C. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00408-4 · Cited by 110
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011
Blake, P. G., Bargman, J. M., Brimble, K. S., Davison, S. N., Hirsch, D. J., McCormick, B. B., Suri, R. S., Taylor, P. A., Zalunardo, N., & Tonelli, M. A. (2011) · Peritoneal Dialysis International · doi:10.3747/pdi.2011.00026 · Cited by 108
Understanding competing risks: a simulation point of view
Allignol, A., Schumacher, M. C., Wanner, C., Drechsler, C., & Beyersmann, J. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-86 · Cited by 108
Self-citationIseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs590 · Cited by 99
Cardiovascular disease in haemodialysis: role of the intravascular innate immune system
Ekdahl, K. N., Soveri, I., Hilborn, J. G., Fellström, B., & Nilsson, B. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.17 · Cited by 104
PTH—A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?
Garrett, G. L., Sardiwal, S., Lamb, E. J., & Goldsmith, D. J. A. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09580911 · Cited by 108
Unfractionated Heparin for Hemodialysis: Still the Best Option
Cronin, R. E., & Reilly, R. F. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00770.x · Cited by 103
de Vries, F. M., Denig, P., Pouwels, K. B., Postma, M. J., & Hak, E. (2012) · Drugs · doi:10.2165/11638240-000000000-00000 · Cited by 116
Vaziri, N. D. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00661.x · Cited by 102
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases
Yamagishi, M., Tamaki, N., Akasaka, T., Ikeda, T., Ueshima, K., Uemura, S., Otsuji, Y., Kihara, Y., Kimura, K., Kimura, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-19-1131 · Cited by 107
Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis
Zhang, S., Lin, H., Wang, J., Rui, J., Wang, T., Cai, Z., Huang, S.-M., Gao, Y., Ma, T., Fan, R., et al. (2025) · Nature · doi:10.1038/s41586-025-08792-8 · Cited by 104
Causes and Consequences of Increased Arterial Stiffness in Chronic Kidney Disease Patients
Gusbeth–Tatomir, P., & Covic, A. C. (2007) · Kidney & Blood Pressure Research · doi:10.1159/000100905 · Cited by 101
Vaziri, N. D. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0847-z · Cited by 101
Keane, W. F., Tomassini, J. E., & Neff, D. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12849 · Cited by 101
Biochemistry and Biomarkers of Inflamed Patients: Why Look, What to Assess
Kaysen, G. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03090509 · Cited by 100
Dyslipidemia in diabetic nephropathy
Kawanami, D., Matoba, K., & Utsunomiya, K. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0028-0 · Cited by 109
Chirakarnjanakorn, S., Navaneethan, S. D., Francis, G. S., & Tang, W. H. W. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.01.015 · Cited by 105
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 94
Self-citationSlinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., Rutks, I., & Wilt, T. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.017 · Cited by 99
Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management
Toussaint, N. D., & Kerr, P. G. (2007) · Nephrology · doi:10.1111/j.1440-1797.2007.00823.x · Cited by 108
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
Isakova, T., Gutiérrez, O. M., & Wolf, M. S. (2009) · Kidney International · doi:10.1038/ki.2009.246 · Cited by 103
Richards, N. N., Harris, K. M., Whitfield, M. G., O'Donoghue, D. J., Lewis, R., Mansell, M. A., Thomas, S., Townend, J., Eames, M., & Marcelli, D. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm857 · Cited by 99
Barylski, M., Nikfar, S., Mikhailidis, D. P., Toth, P. P., Salari, P., Ray, K. K., Pencina, M. J., Rizzo, M., Rysz, J., Abdollahi, M., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.007 · Cited by 98
Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gómez-Campderá, F. J., Vega, A., Abad, S., & Luño, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080938 · Cited by 98
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Farrell, D. R., & Vassalotti, J. A. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03466-5 · Cited by 113
Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease
Kalantar‐Zadeh, K., & Kovesdy, C. P. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02140309 · Cited by 97
Watabe, H., Sato, A., Hoshi, T., Takeyasu, N., Abe, D., Akiyama, D., Kakefuda, Y., Nishina, H., Noguchi, Y., & Aonuma, K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.146 · Cited by 97
Hammer, F., Malzahn, U., Donhauser, J., Betz, C., Schneider, M. P., Grupp, C., Pollak, N., Störk, S., Wanner, C., Krane, V., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.025 · Cited by 96
Self-citationEffects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study
de Oliveira, C. P. M. S., Kappel, C., de Siqueira, É. R. F., Lima, V., Stefano, J. T., Michalczuk, M. T., Marini, S. S., Barbeiro, H. V., Soriano, F. G., Carrilho, F. J., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.016 · Cited by 101
Graham-Brown, M. P. M., March, D. S., Young, R., HIGHTON, P. J., Young, H. M. L., Churchward, D. R., Dungey, M. R., Stensel, D. J., BISHOP, N. C., Brunskill, N. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.02.027 · Cited by 97
Kaysen, G. A., Ye, X., Raimann, J. G., Wang, Y., Topping, A., Usvyat, L. A., Stuard, S., Canaud, B., SANDE, F. M. V. D., Kooman, J. P., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p084277 · Cited by 93
Liu, Y.-W., Su, C.-T., Sung, J., Wang, S. P. H., Su, Y.-R., Yang, C., Tsai, L. M., Chen, J.-H., & Tsai, W. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10671012 · Cited by 97
Herzog, C. A., Strief, J. W., Collins, A. J., & Gilbertson, D. T. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn038 · Cited by 93
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Gregg, L. P., & Hedayati, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.007 · Cited by 91
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 103
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 100
Vitamin D receptor activation and survival in chronic kidney disease
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2008) · Kidney International · doi:10.1038/ki.2008.35 · Cited by 92
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 95
Bae, E. H., Lim, S. Y., Cho, K. H., Choi, J. S., Kim, C. S., Park, J. W., Kwon, S., Jeong, M. H., & Kim, S. W. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.01.016 · Cited by 98
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 96
Saglimbene, V. M., Wong, G., van Zwieten, A., Palmer, S. C., Ruospo, M., Natale, P., Campbell, K. L., Teixeira-Pinto, A. M., Craig, J. C., & Strippoli, G. F. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.02.041 · Cited by 93
Siracusa, C., Carabetta, N., Morano, M. B., Manica, M., Strangio, A., Sabatino, J., Leo, I., Castagna, A., Cianflone, E., Torella, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313096 · Cited by 90
Atherosclerosis in chronic kidney disease: the role of macrophages
Kon, V., Linton, M. F., & Fazio, S. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.157 · Cited by 88
Statins, inflammation and kidney disease
Krane, V., & Wanner, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.62 · Cited by 91
Self-citationMuscle- and skeletal-related side-effects of statins: tip of the iceberg?
Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 94
High-flux versus low-flux membranes for end-stage kidney disease
Palmer, S. C., Rabindranath, K. S., Craig, J. C., Roderick, P. J., Locatelli, F., & Strippoli, G. F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005016.pub2 · Cited by 103
Modification of cardiovascular risk in hemodialysis patients: An evidence‐based review
Johnson, D. W., Craven, A., & Isbel, N. M. (2007) · Hemodialysis International · doi:10.1111/j.1542-4758.2007.00146.x · Cited by 100
Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in Nephrology
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2011.09.004 · Cited by 89
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Self-citationDrechsler, C., Kalim, S., Wenger, J., Suntharalingam, P., Hod, T., Thadhani, R., Karumanchi, S. A., Wanner, C., & Berg, A. H. (2015) · Kidney International · doi:10.1038/ki.2014.429 · Cited by 88
Self-citationKrane, V., Krieter, D. H., Olschewski, M., März, W., Mann, J. F. E., Ritz, E., & Wanner, C. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.026 · Cited by 88
Self-citationCaliff, R. M., Lokhnygina, Y. V., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.004 · Cited by 89
Hanafusa, N., Nakai, S., Iseki, K., & Tsubakihara, Y. (2015) · Kidney International Supplements · doi:10.1038/kisup.2015.5 · Cited by 87
Chung, C. P., Oeser, A. M., Avalos, I., Raggi, P., & Stein, C. M. (2006) · Lupus · doi:10.1177/0961203306071870 · Cited by 87
Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease
Swaminathan, S., & Shah, S. V. (2011) · Kidney International · doi:10.1038/ki.2011.178 · Cited by 89
Insulin Resistance, Inflammation, and Blood Pressure Determine Vascular Dysfunction in CKD
Dogra, G. K., Irish, A. B., Chan, D. C., & Watts, G. F. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.08.008 · Cited by 89
McIntyre, C., McQuillan, R., Bell, C. M., & Battistella, M. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.02.374 · Cited by 90
Kuznik, A., Mardekian, J., & Tarasenko, L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-132 · Cited by 86
Chronic Kidney Disease: Mineral and Bone Disorder in Children
Wesseling‐Perry, K., & Salusky, I. B. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.017 · Cited by 96
Toth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.035 · Cited by 86
Boyd, C. M., Ritchie, C. S., Tipton, E. F., Studenski, S. A., & Wieland, D. (2008) · Aging Clinical and Experimental Research · doi:10.1007/bf03324775 · Cited by 95
Effects of Statins on Renal Function
Agarwal, R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1381 · Cited by 91
Chronic kidney disease mineral and bone disorder in children
Wesseling, K., Bakkaloglu, S. A., & Salusky, I. B. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0671-3 · Cited by 91
Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., II, & Newby, L. K. (2015) · Circulation · doi:10.1161/cir.0000000000000183 · Cited by 96
Fenske, W. K., Wanner, C., Allolio, B., Drechsler, C., Blouin, K., Lilienthal, J., & Krane, V. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070691 · Cited by 89
Self-citationKidney Disease and Cardiovascular Risk
Tonelli, M., & Pfeffer, M. A. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.071105.111123 · Cited by 87
Progress and perspectives in plant sterol and plant stanol research
Jones, P. J. H., Shamloo, M., MacKay, D., Rideout, T. C., Myrie, S. B., Plat, J., Roullet, J., Baer, D. J., Calkins, K. L., Davis, H. R., et al. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy032 · Cited by 95
Appraising Stroke Risk in Maintenance Hemodialysis Patients: A Large Single-Center Cohort Study
Power, A. J., Chan, K., Singh, S. K., Taube, D. H., & Duncan, N. D. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.07.016 · Cited by 85
Public Health Consequences of Chronic Kidney Disease
Weiner, D. E. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.137 · Cited by 85
Diabetes Management Issues for Patients With Chronic Kidney Disease
Cavanaugh, K. L. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.3.90 · Cited by 82
Understanding survival analysis: actuarial life tables and the Kaplan–Meier plot
Barakat, A., Mittal, A., Ricketts, D., & Rogers, B. A. (2019) · British Journal of Hospital Medicine · doi:10.12968/hmed.2019.80.11.642 · Cited by 84
The Cardiovascular Burden in End-Stage Renal Disease
Cozzolino, M. G., Galassi, A., Pivari, F., Ciceri, P., & Conte, F. (2017) · Contributions to nephrology · doi:10.1159/000479250 · Cited by 84
Impact of Kidney Bone Disease and Its Management on Survival of Patients on Dialysis
Lee, G. H., Benner, D. A., Regidor, D. L., & Kalantar‐Zadeh, K. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2006.07.006 · Cited by 85
Lipids and diabetic nephropathy
Rosario, R. F., & Prabhakar, S. S. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0079-7 · Cited by 83
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa498 · Cited by 76
Annual Progression of Coronary Calcification in Trials of Preventive Therapies: A Systematic Review
McCullough, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.382 · Cited by 82
Cardiovascular risk factors in patients with chronic kidney disease
van der Zee, S. A., Baber, U., Elmariah, S., Winston, J. A., & Fuster, V. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.121 · Cited by 97
The Complex Interplay Between Cholesterol and Prostate Malignancy
Solomon, K. R., & Freeman, M. R. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.04.001 · Cited by 88
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
Vupputuri, S. X., Kimes, T. M., Calloway, M. O., Christian, J. B., Bruhn, D. F., Martin, A. A., & Nichols, G. A. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.09.014 · Cited by 82
HMG-CoA reductase inhibitors and the kidney
Campese, V. M., & Park, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002174 · Cited by 81
Statin Use and Calcific Uremic Arteriolopathy: A Matched Case-Control Study
Nigwekar, S. U., Bhan, I., Turchin, A., Skentzos, S. C., Hajhosseiny, R., Steele, D., Nazarian, R. M., Wenger, J., Parikh, S. M., Karumanchi, S. A., et al. (2013) · American Journal of Nephrology · doi:10.1159/000348806 · Cited by 81
Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis
García‐López, E., Carrero, J. J., Suliman, M. E., Lindholm, B., & Stenvinkel, P. (2007) · Peritoneal Dialysis International · doi:10.1177/089686080702702s35 · Cited by 81
Epidemiology of Dialysis Patients and Heart Failure Patients
Kalantar‐Zadeh, K., Abbott, K. C., Kronenberg, F., Anker, S. D., Horwich, T. B., & Fonarow, G. C. (2006) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.09.005 · Cited by 89
Recent progress in the treatment of vascular calcification
O'Neill, W. C., & Lomashvili, K. A. (2010) · Kidney International · doi:10.1038/ki.2010.334 · Cited by 85
Fiedler, R., Jehle, P. M., Osten, B., Dorligschaw, O., & Girndt, M. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp346 · Cited by 80
Ganda, A., Magnusson, M., Yvan‐Charvet, L., Hedblad, B., Engström, G., Ai, D., Wang, T. J., Gerszten, R. E., Melander, O., & Tall, A. R. (2013) · Circulation · doi:10.1161/circulationaha.112.000682 · Cited by 86
Krane, V., for the German Diabetes and Dialysis Study Investigators, Winkler, K., Drechsler, C., Lilienthal, J., März, W., & Wanner, C. (2008) · Kidney International · doi:10.1038/ki.2008.484 · Cited by 79
Self-citationWhy do young people with chronic kidney disease die early?
Kumar, S., Bogle, R., & Banerjee, D. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.143 · Cited by 88
Coll, B., Betriu, À., Martínez‐Alonso, M., Amoedo, M. L., Arcidiacono, M. V., Borràs, M., Valdivielso, J. M., & Fernández, E. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04290510 · Cited by 79
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.